Please login to the form below

Not currently logged in
Email:
Password:

Eisai launches online breast cancer resource

Website includes information on the disease, treatment options and side effects

edit-MBC

Japanese pharma firm Eisai has launched an online portal to provide resources to help women with metastatic breast cancer.

The website, mbcInfoCenter.com, includes information on the disease, treatment options, an overview of common side effects and management techniques, healthy lifestyle tips and strategies to manage finances throughout metastatic breast cancer treatment

Christine Verini, VP of corporate communications and advocacy at Eisai, said: “We are committed to supporting women by providing valuable information and educational resources that address the real-world challenges specific to living with metastatic breast cancer."

According to the company 69% of women perceive access to information as an essential part of their pathway, while 73% seek information about metastatic breast cancer and treatment options on a daily or weekly basis. Peer support is welcome too, with 69% finding it helpful to listen to or read about other people's experiences with breast cancer.

Verini commented: “These statistics suggest the need for centralised online resources to help women with MBC better cope with their disease.

“The launch of mbcInfoCenter.com is an important step in providing MBC patients with a better understanding of their disease and their options, as well as guiding them to communities where they can find support by sharing experiences with other patients.”

Eisai is also sponsoring the 'Hear My Voice' campaign from Living Beyond Breast Cancer (LBBC), an effort to raise awareness for metastatic breast cancer and patients' experiences through the voices of women and men who have lived through the disease.

Eisai has shown a dedicated interest in breast cancer research, with its product Halaven (eribulin) being approved in countries including in Germany, Russia and the US. The drug, however, was not recommended by NICE in the UK due to possible side effects and - despite the company offering a patient access scheme - its cost.

Article by
Kirstie Pickering

16th October 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics